This clinical trial is focused on studying Multiple Myeloma, a type of blood cancer that affects plasma cells in the bone marrow. The study will explore the effectiveness of different treatment strategies using several medications. The main treatments being tested include Isatuximab (also known as SAR650984), which is a humanized monoclonal antibody targeting a protein called CD38, and Lenalidomide, a drug that modifies the immune system. Additionally, Iberdomide (CC-220) and Carfilzomib (PR-171) are also part of the study. These medications are used in various forms such as solutions for infusion, injections, and capsules.

The purpose of the study is to determine the best treatment approach for patients with Multiple Myeloma who are eligible for a procedure called autologous stem cell transplantation. The study will compare different combinations of the medications to see which is more effective in reducing the presence of cancer cells in the bone marrow, a state known as minimal residual disease (MRD) negativity. The trial will involve different groups of patients receiving different treatment plans, including high-dose therapy and additional cycles of the medication combinations.

Participants in the study will receive treatments over a period of time, with some receiving intravenous infusions and others taking oral medications. The study aims to increase the rate of MRD negativity before maintenance therapy, which is a phase of treatment aimed at keeping the cancer from returning. The trial will also look at the long-term outcomes such as overall survival and progression-free survival, which measures the time during and after treatment that a patient lives with the disease without it getting worse. The study is expected to continue until 2028.